Recent Updates
Recently added Catalysts
HELP Positive Sentiment

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Monday, June 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Helus Pharma has successfully closed a $50 million underwritten offering, enhancing its financial stability. This funding will support the execution of the second Phase 3 trial for HLP003, named EMBRACE, which is aimed at a potential U.S. FDA New Drug Application in 2028. The company is optimistic about its future prospects with strong institutional investor backing.
Price reaction · baseline $6.48 (2026-06-26 close) · hit pre-market · clean, no other HELP news in the window
day 0 close · peak
+6.2%
day 1
+2%
day 3
-3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful $50 million underwritten offering strengthens financial position.
  • Institutional investor confidence is high.
  • Funding supports execution of Phase 3 trial for HLP003.

Full Press Release Details

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1, 2,3, EMBRACE, for potential U.S. FDA New Drug Application in 2028 1,2,3 - - Phase 3 APPROACH pivotal study of HLP003 in

Frequently Asked Questions

What recent financial milestone did Helus Pharma achieve?

Helus Pharma closed a $50 million underwritten offering.

What is the purpose of the funding from the offering?

The funding supports the execution of the second Phase 3 trial for HLP003.

What is the timeline for the FDA application for HLP003?

The potential U.S. FDA New Drug Application for HLP003 is targeted for 2028.

How does the offering affect Helus Pharma's financial position?

The offering reinforces investor confidence and bolsters the company's balance sheet.

ShareAdd on Google
Tags: HELP Viatris Investor Conferences Healthcare Helus Pharma HLP003 Phase 3 trial FDA approval financial results
Last updated: Jun 29, 2026

Biotech snapshot

Lead asset
CYB003Phase 3
Major Depressive Disorder →